A Comparison of the Costs of and Quality of Life After Coronary Angioplasty or Coronary Surgery for Multivessel Coronary Artery Disease
- 15 November 1995
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Circulation
- Vol. 92 (10) , 2831-2840
- https://doi.org/10.1161/01.cir.92.10.2831
Abstract
Background The Emory Angioplasty Versus Surgery Trial (EAST) is a randomized trial that compares, by intention to treat, the clinical outcome and costs of percutaneous transluminal coronary angioplasty (PTCA) and coronary surgery for multivessel coronary artery disease. Methods and Results The primary end point was a composite of death, Q-wave myocardial infarction, and a large reversible thallium defect at 3 years. Multiple measures of quality of life also were made. Charges were assessed from the hospital UB-82 bills; professional charges were assessed from the Emory Clinic. Hospital charges were reduced to cost through step-down accounting methods. All costs and charges were deflated to 1987 dollars. Costs were assessed for the initial hospitalization and the cumulative costs of the initial hospitalization and additional revascularization procedures for up to 3 years. There was no difference in mortality or the primary end point. Mean initial hospital charges were $12 654 for the PTCA group and $20 214 for the surgery group ( P <.0001). Professional charges were $4538 for PTCA and $9426 for surgery ( P <.0001). Three-year hospital charges were $19 047 for PTCA and $21 174 for coronary surgery ( P <.0001). Three-year professional charges were $6412 for PTCA and $9861 for surgery ( P <.0001). Three-year total charges were $25 458 for PTCA and $31 033 for surgery ( P <.0001). Total 3-year costs were $23 734 for PTCA and $25 310 for coronary surgery ( P <.0001). There were more hospitalizations for angina and more antianginal medications used in the PTCA group, which would further narrow the differences in cost. Conclusions There was no difference in the primary end point or its components at 3 years. Although the primary procedural costs of coronary surgery are more than for coronary angioplasty, this cost advantage is largely, although probably not completely, lost by 3 years because of more frequent additional procedures and other resource consumption after a first revascularization by PTCA.Keywords
This publication has 17 references indexed in Scilit:
- A Randomized Trial Comparing Coronary Angioplasty with Coronary Bypass SurgeryNew England Journal of Medicine, 1994
- A Randomized Study of Coronary Angioplasty Compared with Bypass Surgery in Patients with Symptomatic Multivessel Coronary DiseaseNew England Journal of Medicine, 1994
- An Introduction to Clinical Microeconomic Analysis: Purposes and Analytic MethodsJournal of Interventional Cardiology, 1994
- Frequency of repeat coronary bypass or coronary angioplasty after coronary artery bypass surgery using saphenous venous graftsThe American Journal of Cardiology, 1994
- Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel disease (ERACI): In-hospital results and 1-year follow-upJournal of the American College of Cardiology, 1993
- Coronary angioplasty versus coronary artery bypass surgery: the Randomised Intervention Treatment of Angina (RITA) trialThe Lancet, 1993
- Changing use of coronary angioplasty and coronary bypass surgery in the treatment of chronic coronary artery diseaseThe American Journal of Cardiology, 1990
- Estimating Physicians' Work for a Resource-Based Relative-Value ScaleNew England Journal of Medicine, 1988
- Clinical, Anatomic and Functional Descriptors Influencing Morbidity, Survival and Adequacy of Revascularization Following Coronary BypassAnnals of Surgery, 1980
- TRANSLUMINAL DILATATION OF CORONARY-ARTERY STENOSISThe Lancet, 1978